16 Feb
2021

The CAFC’s Amgen v Sanofi decision spells trouble for broad functional patent claims

The CAFC’s much-anticipated ruling has major implications for antibody patents and continues the court’s trend of imposing a tough enablement standard for genus claims

Adam Houldsworth

Author | Life sciences reporter

[email protected]

Adam Houldsworth